InhaleRx Limited (ASX:IRX)

The document is the Appendix 4C quarterly cash flow report for InhaleRx Limited for the quarter ending 31 December 2025. It details the company's cash flows from operating, investing, and financing activities. InhaleRx reported a net cash outflow of $628,000 from operating activities, largely due to payments for research and development, advertising, marketing, and administrative costs, offset by government grants and tax incentives. There were no significant cash flows from investing activities, while financing activities generated a net inflow of $894,000, mainly from proceeds of borrowings and the issue of equity securities, despite transaction costs. The company has secured a funding facility of up to $38.5 million from Linlithgow Family Office to cover clinical trial costs for its drug development plans over the next 2-3 years. As of the quarter's end, InhaleRx had cash and cash equivalents of $436,000 and unused finance facilities amounting to $50,787,000, providing an estimated 81.57 quarters of funding.